Literature DB >> 15027512

The accelerated biased coin up-and-down design in phase I trials.

Mario Stylianou1, Dean A Follmann.   

Abstract

The biased coin up-and-down design (BCD) is used to allocate doses in phase I clinical trials. The BCD requires that the treatment response or the toxicity evaluation is observed quickly. In trials with a long treatment evaluation, the BCD will lead to long trial duration because a new patient cannot be enrolled until the preceding patient has completed the evaluation period. We propose a simple method to modify the BCD that will reduce the trial duration without significantly affecting the estimate of the target dose. The idea is to allocate a dose to each patient as he or she arrives based on the toxicity information of the last completed subject. This allows multiple patients to be concurrently under evaluation. A simulation study shows that this modification does not adversely affect the precision of the recommended dose, as estimated by isotonic regression, but it does significantly reduce the total time to complete the study.

Entities:  

Mesh:

Year:  2004        PMID: 15027512     DOI: 10.1081/bip-120028518

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  4 in total

1.  Up-and-down designs for phase I clinical trials.

Authors:  Suyu Liu; Chunyan Cai; Jing Ning
Journal:  Contemp Clin Trials       Date:  2013-07-13       Impact factor: 2.226

2.  A comparative study of Bayesian optimal interval (BOIN) design with interval 3+3 (i3+3) design for phase I oncology dose-finding trials.

Authors:  Yanhong Zhou; Ruobing Li; Fangrong Yan; J Jack Lee; Ying Yuan
Journal:  Stat Biopharm Res       Date:  2020-09-14       Impact factor: 1.452

3.  A software tool for both the maximum tolerated dose and the optimal biological dose finding trials in early phase designs.

Authors:  Chen Li; Hongying Sun; Cheng Cheng; Li Tang; Haitao Pan
Journal:  Contemp Clin Trials Commun       Date:  2022-09-13

Review 4.  Dose escalation methods in phase I cancer clinical trials.

Authors:  Christophe Le Tourneau; J Jack Lee; Lillian L Siu
Journal:  J Natl Cancer Inst       Date:  2009-05-12       Impact factor: 13.506

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.